{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:30:03Z","timestamp":1786120203074,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/cad.0b013e32834a2c70","type":"journal-article","created":{"date-parts":[[2011,8,5]],"date-time":"2011-08-05T09:44:44Z","timestamp":1312537484000},"page":"1002-1009","source":"Crossref","is-referenced-by-count":20,"title":["HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro"],"prefix":"10.1097","volume":"22","author":[{"given":"Stefan","family":"Vallo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Hudak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Juengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Tsaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wiesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Haferkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman A.","family":"Blaheta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210203","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/cncr.24760","article-title":"Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates.","volume":"116","author":"Edwards","year":"2010","journal-title":"Cancer"},{"key":"R2-7-20210203","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(09)60491-8","article-title":"Bladder cancer.","volume":"374","author":"Kaufman","year":"2009","journal-title":"Lancet"},{"key":"R3-7-20210203","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00120-006-1065-z","article-title":"Noninvasive and invasive bladder cancer: diagnostics and treatment.","volume":"45","author":"Goebell","year":"2006","journal-title":"Urologe A"},{"key":"R5-7-20210203","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1097\/00001813-199711000-00007","article-title":"Sodium valproate inhibits in vivo growth of human neuroblastoma cells.","volume":"8","author":"Cinatl","year":"1997","journal-title":"Anticancer Drugs"},{"key":"R6-7-20210203","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/00001813-199609000-00008","article-title":"Antitumor activity of sodium valproate in cultures of human neuroblastoma cells.","volume":"7","author":"Cinatl","year":"1996","journal-title":"Anticancer Drugs"},{"key":"R7-7-20210203","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/med.20027","article-title":"Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies.","volume":"25","author":"Blaheta","year":"2005","journal-title":"Med Res Rev"},{"issue":"8B","key":"R8-7-20210203","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1111\/j.1582-4934.2008.00436.x","article-title":"The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo.","volume":"13","author":"Jones","year":"2009","journal-title":"J Cell Mol Med"},{"issue":"8B","key":"R9-7-20210203","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1111\/j.1582-4934.2008.00603.x","article-title":"Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix.","volume":"13","author":"Jones","year":"2009","journal-title":"J Cell Mol Med"},{"issue":"suppl","key":"R10-7-20210203","doi-asserted-by":"crossref","first-page":"e13596","DOI":"10.1200\/jco.2010.28.15_suppl.e13596","article-title":"Use of genomic signatures to predict response to histone deacetylase inhibitors and correlation with tumor subtypes and molecular pathways.","volume":"28","author":"Cohen","year":"2010","journal-title":"J Clin Oncol"},{"key":"R12-7-20210203","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/sj.bjc.6603777","article-title":"Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium.","volume":"96","author":"Blaheta","year":"2007","journal-title":"Br J Cancer"},{"key":"R13-7-20210203","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/0008-5472.CAN-03-2043","article-title":"Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824.","volume":"64","author":"Atadja","year":"2004","journal-title":"Cancer Res"},{"key":"R14-7-20210203","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1182\/blood.V94.4.1401.416k30_1401_1408","article-title":"Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells.","volume":"94","author":"Byrd","year":"1999","journal-title":"Blood"},{"issue":"Suppl 2","key":"R15-7-20210203","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1038\/sj.cdd.4401535","article-title":"Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.","volume":"11","author":"Inoue","year":"2004","journal-title":"Cell Death Differ"},{"key":"R16-7-20210203","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/1756-9966-29-149","article-title":"Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line.","volume":"29","author":"Yagi","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"key":"R17-7-20210203","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4149\/neo_2011_01_35","article-title":"Epigenetic modulation of gene expression of human leukemia cell lines - induction of cell death and senescence.","volume":"58","author":"Elknerova","year":"2011","journal-title":"Neoplasma"},{"key":"R18-7-20210203","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2146\/ajhp090247","article-title":"Vorinostat. A novel therapy for the treatment of cutaneous T-cell lymphoma.","volume":"67","author":"Kavanaugh","year":"2010","journal-title":"Am J Health Syst Pharm"},{"key":"R20-7-20210203","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2009.24.9094","article-title":"Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer.","volume":"28","author":"Ramalingam","year":"2010","journal-title":"J Clin Oncol"},{"key":"R21-7-20210203","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/1078-0432.CCR-08-1930","article-title":"Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase III trial of valproic acid and epirubicinFEC.","volume":"15","author":"Munster","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R22-7-20210203","first-page":"3769","article-title":"Cyclin-mediated G1 arrest by celecoxib differs in low-versus high-grade bladder cancer.","volume":"29","author":"Gee","year":"2009","journal-title":"Anticancer Res"},{"key":"R23-7-20210203","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1158\/0008-5472.CAN-04-2074","article-title":"Differential expression of cell cycle regulators in phenotypic variants of transgenically induced bladder tumors: implications for tumor behavior.","volume":"65","author":"Garcia-Espana","year":"2005","journal-title":"Cancer Res"},{"key":"R24-7-20210203","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/carcin\/21.5.857","article-title":"Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis.","volume":"21","author":"Weinstein","year":"2000","journal-title":"Carcinogenesis"},{"key":"R25-7-20210203","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.3346\/jkms.2010.25.10.1449","article-title":"Expression of pRb, p53, p16 and cyclin D1 and their clinical implications in urothelial carcinoma.","volume":"25","author":"Lee","year":"2010","journal-title":"J Korean Med Sci"},{"key":"R26-7-20210203","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1309\/LTFU3UUMBY095HUM","article-title":"Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters.","volume":"122","author":"Lopez-Beltran","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"R27-7-20210203","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/1078-0432.CCR-05-1344","article-title":"Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wntbeta-catenin signaling pathway.","volume":"12","author":"Urakami","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R28-7-20210203","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.eururo.2006.03.027","article-title":"Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder.","volume":"50","author":"Yurakh","year":"2006","journal-title":"Eur Urol"},{"key":"R29-7-20210203","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.humpath.2006.05.017","article-title":"Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis.","volume":"37","author":"Shariat","year":"2006","journal-title":"Hum Pathol"},{"key":"R31-7-20210203","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/modpathol.3800757","article-title":"Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness.","volume":"20","author":"Shariat","year":"2007","journal-title":"Mod Pathol"},{"key":"R32-7-20210203","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1054\/bjoc.2000.1736","article-title":"Decreasing of p27 Kip1 and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer.","volume":"84","author":"Kamai","year":"2001","journal-title":"Br J Cancer"},{"key":"R33-7-20210203","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000113792","article-title":"Large-scale analysis of cell cycle regulators in urothelial bladder cancer identifies p16 and p27 as potentially useful prognostic markers.","volume":"75","author":"Brunner","year":"2008","journal-title":"Pathobiology"},{"key":"R34-7-20210203","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/j.1442-2042.2007.01896.x","article-title":"Overexpression of p27kip1 in urinary bladder urothelial carcinoma.","volume":"14","author":"Fu","year":"2007","journal-title":"Int J Urol"},{"key":"R35-7-20210203","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1479-0556-5-10","article-title":"HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo.","volume":"5","author":"Segura-Pacheco","year":"2007","journal-title":"Genet Vaccines Ther"},{"key":"R36-7-20210203","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(08)70004-4","article-title":"Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis.","volume":"9","author":"Weichert","year":"2008","journal-title":"Lancet Oncol"},{"key":"R37-7-20210203","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4161\/epi.3.1.5736","article-title":"HDACs and HDAC inhibitors in colon cancer.","volume":"3","author":"Mariadason","year":"2008","journal-title":"Epigenetics"},{"key":"R39-7-20210203","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/bjc.2011.13","article-title":"Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours.","volume":"104","author":"Razak","year":"2011","journal-title":"Br J Cancer"},{"key":"R40-7-20210203","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2009.24.9094","article-title":"Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer.","volume":"28","author":"Ramalingam","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CAD.0b013e32834a2c70","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:14:07Z","timestamp":1786047247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-201111000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e32834a2c70","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}